碳酸锂联合氨磺必利或氯氮平治疗女性躁狂发作对照研究

摘要

目的 探讨碳酸锂分别联合氨磺必利、氯氮平治疗女性躁狂发作的临床疗效及安全性.方法 将100例女性躁狂症患者按照随机数字表法分为两组,每组50例.实验组予以碳酸锂联合氨磺必利治疗,对照组予以碳酸锂联合氯氮平治疗.观察8周.于治疗前后采用躁狂量表、副反应量表评定临床疗效及不良反应. 结果 治疗1周末起两组躁狂量表评分均较治疗前显著降低(P<0.01);同期两组间比较,治疗1周末实验组显著高于对照组(P<0.01),其他时间点两组比较差异无统计学意义(P>0.05).实验组副反应量表评分显著低于对照组(P<0.01).实验组不良反应发生率为26%,对照组为76%,实验组显著低于对照组(P<0.01).结论 碳酸锂联合氨磺必利或氯氮平治疗女性躁狂症疗效均显著,且相当,但碳酸锂联合氨磺必利安全性更高.%Objective To explore the efficacy of lithium carbonate plus amisulpride or clozapine in the treatment of female manic episode.Methods A total of 100 female mania patients were randomly divided into groups of 50 ones each.Experimental group was treated with lithium carbonate plus amisulpride and control with lithium carbonate plus clozapine for 8 weeks.Efficacies were assessed with the Bech-Rafaelsen Mania Scale (BRMS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) before and after treatment.Results Since the end of the 1st week the BRMS scores of both groups higher more significantly compared with pretreatment (P<0.01), that was significantly lower in experimental than in control group at the end of the 1st week (P<0.01), and there were no significant differences in those at other time points (P>0.05).The TESS score was significantly lower in experimental than in control group (P<0.01).The incidence of adverse reactions was respectively 26% in experimental and 76% in control group and the former significantly lower than the latter (P<0.01).Conclusion Lithium carbonate plus amisulpride or clozapine is effective and equivalent in the treatment of female manic episode, but lithium carbonate plus amisulpride has higher safety.